학술논문
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
Document Type
article
Author
M. G. Filippone; D. Gaglio; R. Bonfanti; F. A. Tucci; E. Ceccacci; R. Pennisi; M. Bonanomi; G. Jodice; M. Tillhon; F. Montani; G. Bertalot; S. Freddi; M. Vecchi; A. Taglialatela; M. Romanenghi; F. Romeo; N. Bianco; E. Munzone; F. Sanguedolce; G. Vago; G. Viale; P. P. Di Fiore; S. Minucci; L. Alberghina; M. Colleoni; P. Veronesi; D. Tosoni; S. Pece
Source
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
Finding biomarkers for targeted therapy is a promising approach to treat cancer. Here, the authors show that in breast cancer preclinical models and patients, CDK12 promotes tumourigenesis but induces selective vulnerability to therapies that target folate one-carbon metabolism.